Methods of using SCAP antagonists

Details Methods of using SCAP antagonists Methods of using SCAP antagonists

2000-07-13

2004-01-06

Kunz, Gary (Department: 1647)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S011000, C514S002600, C514S012200, C514S824000, C514S866000, C530S350000, C530S359000

Reexamination Certificate

active

06673555

ABSTRACT:

FIELD OF THE INVENTION
This application claims priority to Great Britain Application No. GB 9916757.9 filed Jul. 17, 1999.
The present invention relates to the novel use of the SREBP-cleavage activating protein (SCAP) in a screening method, particularly a method of screening for agents which compete for binding on SCAP, and to agents having SCAP binding characteristics for use in combating diseases associated with elevated lipid levels.
BACKGROUND
Cholesterol is transported in the blood in the form of protein/lipid complexes termed lipoproteins. Each lipoprotein plays a role in the transport of lipid from peripheral tissues to the liver or vice versa. Prolonged elevation of some of these classes of lipoproteins can lead to deposition of cholesterol and cholesterol esters in the arteries which may in turn lead to arterial occlusion and clinical conditions such as myocardial infarction and heart failure.
Numerous studies have shown a correlation between extent of atherosclerosis and the incidence of myocardial infarction and plasma level of low density lipoprotein (reviewed by Simon A et al.,
Circulation
96:2449-2452 (1997)). During the past decade, several clinical trials using inhibitors of HMGCoA-reductase, the rate limiting enzyme of cholesterol synthesis, have confirmed the beneficial effect of decreasing plasma LDL levels on cardiovascular mortality (Brown A. S. et al.,
J. Am. Coll. Cardiol
. 32:665-672 (1998). The mechanism by which cholesterol depletion in hepatic cells prevents the down regulation of the LDL receptor, which mediates LDL re-uptake, has been well characterised by Brown and Goldstein (reviewed in
Cell
89:331-340 (1997)). They have identified a responsive element in the LDL-receptor promoter which is involved in LDL-receptor regulation by sterols, the Sterol Responsive Element (SRE) (Briggs M. R. et al.,
J. Biol. Chem
. 268:14490-14496 (1993)). They have purified and cloned two SRE binding proteins (SREBPs) present as precursor forms in the endoplasmic reticulum membrane (Yokoyama C. et al.,
Cell
75:187-197 (1993) and Hua X. et al.,
Proc. Natl. Acad. Sci
. 90:11603-11607 (1993). Upon cholesterol depletion, these membrane bound forms are sequentially cleaved by two recently cloned proteases, S-1-P (Sakai J et al,
Mol. Cell
, 2:505-514 (1998)), and S-2-P (Rawson R. B. et al,
Mol. Cell
, 1:47-57 (1997)), and the mature forms thus released, migrate to the nucleus and bind to SRE (Sakai J. et al,
Cell
85:1037-1046 (1996). The SREBP-cleavage activating protein (SCAP) has been identified and shown to interact physically with SREBPs (Sakai J. et al.,
J. Biol. Chem
. 272:20213-20221 (1997). The presence of a putative sterol binding domain on SCAP between amino acid 280 to 444 further suggests its role is that of a “cholesterol sensor” (Hua X. et al.;
Cell
87:415-426 (1996)). Excess cholesterol in the cell, presumably prevents the SCAP/SREBP interaction, thus blocking the SREBP proteolytic maturation process. Cholesterol and its metabolites act as repressors of genes that increase cellular cholesterol content e.g. those catalysing de novo cholesterol synthesis or mediating uptake of cholesterol-rich LDL (Javitt N. B.,
Faseb
9:1378-1381 (1995)). The water-soluble cholesterol analogue 25OH-cholesterol is a potent suppressor of sterol-regulated genes (Brown M. S. and Goldstein J. L.,
J. Biol. Chem
., 249:7306-7314 (1974)) and has been used to study SCAP function (Nohturfft A. et al.,
Proc. Natl. Acad. Sci
. 93:13709-13714 (1996)).
SUMMARY OF THE INVENTION
A first aspect of the invention is a method for screening for a SCAP antagonist for use in combating diseases associated with circulating elevated levels of LDL-cholesterol, said method comprising detecting or assaying the extent or result of transcriptional activity or binding competition on SCAP between a test SCAP antagonist and a control SCAP antagonist, or between a test SCAP antagonist and cholesterol, or a metabolite thereof.
In an alternative or yet further aspect, there is provided a method for the treatment of conditions resulting from elevated circulating levels of LDL-cholesterol and/or triglycerides comprising administration of a SCAP antagonist.


REFERENCES:
patent: 6372724 (2002-04-01), Pelleg et al.
patent: 6387913 (2002-05-01), Mustafa
Horton et al., “Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis,”Current Opinion in Lipidology10:143-150 (1999).
Kovanen et al., “Regulation of the low density lipoprotein (B/E) receptor,”Advances in Vascular Biology5:165-185 (1999).
Aguilar-Salinas et al., “Metabolic modes of action of the statins in the hyperlipoproteinemias,”Atherosclerosis141:203-207 (1998).
Chan et al., “Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet,”J. Nutr.129(6):1094-1101 (Jun. 1999).
Draijer et al., “HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice,”Biochemical Pharmacology63:1755-1761 (2002).
Grand-Perret et al., “SCAP ligands are potent new lipid-lowering drugs,”Nature Medicine7(12):1332-1338 (Dec. 2001).
Hoffmann et al., “Cholesterol lowering action of HOE 402 in the normolipidemic and hypercholesterolemic Golden Syrian hamster,”Biochimica et Biophysica Acta1299:95-102 (1996).
Korn et al., “Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N),”J. Clin. Invest.102(12):2050-2060 (Dec. 1998).
Lange et al., “Four cholesterol-sensing proteins,”Curr. Opin. Struct. Biol.8(4):435-439 (Aug. 1998).
Liu et al., “Oncostatin M activates low density lipoprotein receptor gene transcription in sterol-repressed liver Cells,”Cell Growth&Differentiation5:1333-1338 (Dec. 1994).
Liu et al., “Novel mechanism of transcriptional activation of hepatic LDL receptor by oncostatin M,”Journal of Lipid Research38:2035-2048 (1997).
Meier, “Regulation of cholesterol synthesis: of SCAP, SREBP, CBP and more,”Eur. J. Endocrinol136(3):271-272 (Mar. 1997).
Osbourne, “Cholesterol homeostasis: Clipping out a slippery regulator,”Current Biology7:R172-R174 (1997).
Thompson et al., “Novel lipid-regulating drugs,”Expert Opin. Investig. Drugs9(11):2619-2628 (2000).
Wang et al., “Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter,”The Journal of Biological Chemistry268(19):14497-14504 (Jul. 1993).
Nohturfft Axel et al: “Sterols regulate processing of carbohydrate chains of wild-type SREBP cleavage-activating protein (SCAP), but not sterol-resistant mutants Y298C or D44N”, Proceedings of the National Academy of Sciences of the United States, vol. 95, No. 22, Oct. 27, 1998, pp. 12848-12853.
Nohturfft Axel et al: “Topology of SREBP cleavage-activating protein, a polytopic membrane protein with a sterol-sensing domain”, Journal of Biological Chemistry, vol. 273, No. 27, Jul. 3, 1998, pp. 17243-17250.
Fajas Lluis et al: “Regulation of Peroxisome Proliferator-Activated Receptor y Expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: Implications for Adipocyte Differentiation and Metabolism”, Molecular adn Cellular Biology, 1999, vol. 19, No. 8, pp. 5495-5503.
A. Simon et al., Circulation, vol. 96, 1997, pp. 2449-2452.
A.S. Brown et al., J. Am. Coll. Cardiol., vol. 32, 1998, pp. 665-672.
Cell, vol. 89, 1997, pp. 331-340.
M.R. Briggs et al., J. Biol. Chem., vol. 268, 1993, pp. 14490-14496.
C. Yokoyama et al., Cell, vol. 75, 1993, pp. 187-197.
X. Hua et al., Proc. Natil. Acad. Sci., vol. 90, 1993, pp. 11603-11607.
J. Sakai et al., Mol. Cell, vol. 2, 1998, pp. 505-514.
R.B. Rawson et al., Mol. Cell, vol. 1, 1997, pp. 47-57.
J. Sakai et al., Cell, Vol. 85, 1996, pp. 1037-1046.
J. Sakai et al., J. Biol. Chem., vol. 272, 1997, pp. 20213-20221.
X. Hua et al., Cell, vol. 87, 1996, pp. 415-426.
N.B. Javitt, Faseb, vol. 9, 1995, p. 1378-1381.
M.S. Brown and J.L. Goldstein, J. Biol. Chem., vol. 249, 1974, pp.

Affiliated with

Also associated with

Rating

Methods of using SCAP antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using SCAP antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using SCAP antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3253376